From MarketBeat:

REGENXBIO Inc. CEO Kenneth T. Mills sold 45,000 shares of the stock at an average price of $15.18, totaling $683,100. Following the sale, Mills holds 408,035 shares valued at $6,193,971. The transaction was disclosed in a document filed with the SEC and is available through their website.

REGENXBIO Inc. shares traded down $0.39, reaching $13.77. The firm has a market capitalization of $605.74 million, with a price-to-earnings ratio of -2.30 and a beta of 1.20. Twelve month low is $12.76 and high is $25.32. In the last quarter, REGENXBIO posted ($1.41) EPS, beating consensus estimates by $0.03.

Equities research analysts gave REGENXBIO ratings of “hold” and “buy.” The company has a consensus rating of “Hold” and a consensus target price of $31.25. Royal Bank of Canada has a “sector perform” rating with a target of $20.00. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating.

Institutional investors have increased their holdings in REGENXBIO, including Captrust Financial Advisors, Royal Bank of Canada, Northwestern Mutual Wealth Management Co., PNC Financial Services Group Inc., and Headlands Technologies LLC.

REGENXBIO Inc. provides gene therapy product candidates to deliver genes to cells to address genetic defects or produce therapeutic proteins or antibodies. Their gene therapy product candidates are based on NAV Technology Platform.

This news was generated by narrative science technology and financial data from MarketBeat, providing fast and accurate reporting. Prior to publication, this story was reviewed by MarketBeat’s editorial team. For questions or comments, contact [email protected]



Read more: Kenneth T. Mills Sells 45,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) Stock